Indevus licenses Schering's Nebido

Indevus will pay $30 million for US rights to Schering's Nebido, a testosterone-replacement injection that lasts for three months. The money includes up-front, regulatory milestone, and commercialization milestone payments, including $7.5 million up-front and $5 million upon approval of the product. Nebido was recently approved and launched in Europe "Our acquisition of rights to Nebido in the US is a major step in the execution of our corporate strategy. Leveraging and building on our existing franchise in urology has been our highest priority since the launch of Sanctura," said Glenn L. Cooper, MD, chairman, president and CEO of Indevus.

- read this press release for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.